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INTERMEDIATE-RISK PROSTATE CANCER, ANDROGEN 
DEPRIVATION THERAPY AND THE RISK OF DEATH 
Tom Pickles, Scott Tyldesley, Mira Keyes, W James Morris 
University of British Columbia, Vancouver, BC 
 
Purpose: Intermediate-risk prostate cancer comprises a 
heterogenous group, whose management includes external 
radiation (EBRT), brachytherapy (brachy), or surgery. Androgen 
deprivation therapy (ADT) has been shown to improve survival in 
IR prostate cancer when combined with standard dose EBRT 
(RTOG 9408). Its role with brachy is unclear, but appears to add 
10-15% absolute improvement in biochemical control (as 
presented at CARO 2015). In our practice the use of ADT in this 
context has declined from 91% in 1990 to 21% in 2015, because 
of uncertainty of its role, and concerns of toxicity. The aim of 
this study was to examine the effect of ADT on subsequent 
survival of men treated for IR with brachy. 
Methods and Materials: Men treated for IR prostate cancer 1998-
2011 were prospectively followed in an outcomes database. They 
were risk grouped using the ProCars scheme into low- and high-
IR. Endpoints were biochemical control (bNED, by the Phoenix, 
nadir + 2 definition) and survival. Death information was 
obtained from the provincial cancer registry. Cause of death was 
ascribed to prostate cancer, cardiovascular disease, other cause, 
or unknown. bNED and survival were calculated using the Kaplan-
Meier method with log-rank statistics, and multivariable analysis 
performed.  
Results: 2232 men form the study cohort. Eighty-seven percent 
had low-IR cancer, and 13% high-IR. Six months of neoadjuvant 
and concurrent ADT was used in 50%. Ninety-nine percent 
received 125I low dose rate permanent brachytherapy 
monotherapy (144 Gy) and 1% received 115 Gy plus pelvic EBRT, 
(46 Gy). Median follow up for bNED is five years (range 0-17) and 
for survival seven years (4-17, with 23% followed for more than 
10 years). Actuarial biochemical control at 10 years is 74% 
without, and 88% with ADT (p < 0.001), and both low-IR (77% 
versus 86%) and high-IR (68% versus 83% at six years) show this 
improvement. Overall survival is 89% without ADT and 85% with 
ADT at 10 years (p = 0.041). Cardiovascular deaths were 
significantly increased with ADT (5% versus 2.3% at 10 years, p = 
0.015), and contribute to the decreased overall survival 
observed. Prostate cancer deaths occurred in 0.5% and 1.5% 
without and with ADT, at 10 years. Multivariable analysis shows 
that the excess cardiac deaths are due to comorbidity and age. 
Conclusions: Although bNED is improved by the addition of six 
months of ADT, overall survival is worse when examined in a 
mature dataset. This detriment is due to excess non-prostate 
causes, including cardiovascular deaths. The main drivers of the 
latter appear to be presence of cardiac risk factors, other 
comorbidity, and age. The use of ADT may be a particular 
concern in patients with such risk factors. Benefits, risks, and 
patient preference should be considered when determining the 
addition of ADT with BT for IR prostate cancer. 
 
69 
ACUTE COMPLICATIONS OF PERINEAL INTERSTITIAL 
BRACHYTHERAPY (ISBT) IMPLANTS IN GYNECOLOGICAL CANCER 
PATIENTS: PROSPECTIVE ANALYSIS OF ORGAN INJURY AND 
INFECTION  
Lucas C. Mendez1, Lisa Barbera2, David D'Souza3, Laura 
D'Alimonte2, Eric Leung2 
1University of São Paulo, São Paulo, Brazil 
2University of Toronto, Toronto, ON 
3University of Western Ontario, London, ON 
 
Purpose: Brachytherapy is an integral component of radiation 
treatment of gynecological malignancies. Many locally-advanced 
pelvic tumours may not be adequately controlled with 
intracavitary techniques due to challenges in dose conformality. 
ISBT can improve dosimetry through the insertion of catheter 
needles directly into tumour tissue. However, due to its 
invasiveness and potential risks of complications, there is a lack 
of expertise in ISBT. The goal is to evaluate the safety of ISBT by 
studying the acute complications with a perineal applicator 
technique. 
Methods and Materials: Thirty-nine patients at a single 
institution treated with high-dose rate perineal ISBT from 
September 2014 to January 2016 were included in a prospective 
registry trial. Median age was 65 (range 23-88) with 13 cervical 
cancer patients, 11 vaginal, 11 recurrent endometrial, one 
vulvar. Three patients were treated palliatively. No bowel 
preparation was used prior to implant and no antibiotics were 
given perioperatively. Post-procedure, patients were imaged 
with CT or MRI with no attempt to adjust needle depth or position 
after review of imaging. First follow up visit occurred within 6 
weeks after treatment and then 2-3 months later. Post-operative 
adverse events were graded with CTCAE V3.0 and radiation 
related toxicity with RTOG common criteria.  
Results: Median follow up time was three months. Thirty-four 
patients were initially treated with external beam radiation 
therapy to the pelvis with a dose of 45 Gy (median). A total of 
56 implants were performed; 22 patients received one implant 
while 17 had two. Median hospital stay was two days (1-5). The 
median number of needles for each implantation was 17 (8-26). 
The most commonly invaded organ by the interstitial catheters 
was the bladder (13) followed by bowel (10) and rectum (nine). 
Eighteen patients had radiological evidence of needle intrusion 
to a pelvic organ and six patients had more than one pelvic organ 
punctured by the catheters. Two acute organ complications 
attributable to needle intrusion to the bladder were found. One 
patient developed G1 hematuria and was discharged without 
delay and another had G2 hematuria requiring manual saline 
irrigation. No GI complications were found. Three patients 
developed perineal cellulitis post-ISBT. Acute radiation-related 
toxicities were seen in six patients with Grade 1 GI and/or GU. 
Conclusions: ISBT is a safe and feasible treatment for locally-
advanced gynecological cancers. With no attempted post-
treatment adjustment, radiological evidence of needle intrusion 
into pelvic organs is a common finding. No severe organ 
complications were found and the rate of acute complications 
are low. Vulva and perineal infection post-ISBT was the most 
common complication related to needle implantation. The 
development of real-time image-guidance may improve implant 
positioning for tumour coverage but likely will not affect the 
existing low rate of acute organ complications. 
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Purpose: To compare results of radical prostatectomy (RP) and 
permanent seed prostate brachytherapy (PB) is difficult because 
of different definitions for recurrence and differences in baseline 
characteristics. We analyzed treatment results of both 
treatments in low- and low-intermediate prostate cancer 
patients from a single tertiary centre using similar definitions for 
biochemical recurrence. 
Methods and Materials: Patients were selected from each 
department’s internal database based on pre-operative selection 
criteria from NCCN guidelines (2015) for low- and low-
intermediate-risk patients. All selected patients had complete 
data on Gleason score, clinical staging and pre-treatment 
prostate specific antigen (PSA) value and none had received any 
neo-adjuvant androgen deprivation therapy. The end point was 
biochemical recurrence (BCR) or any salvage treatment for both 
RP and PB at 48 (± 4) months after treatment. The biochemical 
relapse threshold was set at PSA ≥ 0.5ng/mL for PB and two PSA 
values ≥ 0.2 ng/mL for RP. Patients from both treatment groups 
were compared using non-parametric tests. A binary logistic 
regression analysis was done to test an association of treatment 
and pre-treatment factors with a BCR at 48 months. 
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Results: Five hundred and seventy-five patients were included, 
254 treated with RP and 321 with PB. At RP, 24% had pT3 disease. 
The positive surgical margin rate was 50% and 21% for patients 
with pT3 and pT2 respectively. The median D90 (dose [Gy] that 
covers 90% of the prostate volume) in this study was 159.1 Gy 
(IQR 140.9-176.7 Gy). The D90 was < 130 Gy in 14% of implants. 
Patients who had RP were compared to patients treated with PB: 
RP patients were significantly younger, had less positive pre-
treatment biopsies but a lower rate of Gleason 7 disease. The 
mean PSA was not different. The rate of patients with BCR was 
not different between both groups (p = 0.24) and occurred in 
21.2% after RP and in 20.6% after PB. On univariate and 
multivariate logistic regression analysis, younger age, higher 
percentage of positive biopsies and initial PSA were predictive of 
BCR. Treatment modality was not predictive in either univariate 
(OR 0.96, 95%CI 0.64-1.44 p = 0.58) or multivariate (OR 1.42, 
95%CI 0.88-2.28, p = 0.42) analyses. 
Conclusions: Both RP and PB result in similarly good results at 
four years post treatment with about 20% experiencing BCR, as 
measured with similar PSA-thresholds. Clinical T-Stage, age, 
percentage of positive biopsies and Gleason score are predictive 
of outcome. However, it is possible that study power is 
inadequate and/or follow up is too short to detect a difference 
between both treatments. 
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ANALYSIS FOR 3392 CONSECUTIVE 125-IODINE MONOTHERAPY 
PATIENTS  
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Purpose: To investigate the effect of D90 on biochemical failure 
in a large consecutive cohort of I125 monotherapy patients. 
Methods and Materials: Between July 1998 and September 2011, 
3436 men with NCCN low- and intermediate-risk prostate cancer 
underwent I125 brachytherapy monotherapy, 3392 (98.6%) of 
whom had post-implant, CT-based dose metrics recorded. Sixty 
percent had intermediate-risk disease and 46% had six months of 
neoadjuvant/concomitant androgen deprivation therapy (ADT). 
The median D90 was 153 Gy (mean 154 Gy, SD 15.9, range 86.5-
223 Gy).The median follow up was 5.48 years (mean 6.12, SD 
3.95, range 0-16.9); 648 men have been followed for at least 10 
years. 
Results: As of September 2015, there have been 222 biochemical 
relapse events (nadir+2 ng/mL threshold) yielding five- and 10-
year K-M biochemical progression free survival (b-PFS) estimates 
of 94.9% (± 1.0%) and 89.9% (± 1.6%) respectively. Intermediate-
risk patients were more than twice as likely to experience 
biochemical failure compared to low-risk (HR 2.13, p < 0.001). In 
a multivariate Cox model, Gleason sum 7 versus ≤6 (HR 2.2, p < 
0.001), pre-treatment PSA (HR 1.14 per unit increase, p < 0.001) 
and clinical T2b-c versus T1c-T2a (HR 1.8, p < 0.001) were each 
strongly associated with increased risk of biochemical failure. 
The use of ADT reduced the risk of biochemical failure (HR 0.51, 
p < 0.001). Post-implant D90 values, age and percent positive 
cores were not statistically associated with biochemical relapse 
in MVA. Although not reaching statistical significance, a small 
dose effect was identified when comparing the annualized risk 
of relapse for years 4-9 post-implant permitting a quantitative 
estimate of the impact of D90 on b-PFS. For intermediate-risk 
patients who did not receive ADT (n = 1019), D90 had no 
measurable impact on the risk of biochemical failure. However, 
for the intermediate-risk patients who did receive ADT (n = 
1085), there was a 1.8% improvement in the ten-year b-PFS for 
each 10 Gy increase in D90. For the low-risk patients, there was 
a 1.4% improvement in the ten-year b-PFS for each 10 Gy 
increase in D90. 
Conclusions: The three conventional prognostic factors (Gleason 
sum, pre-treatment PSA and clinical T-Stage) as well as the use 
of ADT were all strongly associated with biochemical failure in 
MVA. D90 did not reach statistical significance in MVA, but a 
small beneficial effect of increased D90 values was identified. 
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Purpose: To report preliminary outcomes of focal salvage HDR 
brachytherapy for locally recurrent prostate cancer after 
external beam radiotherapy (RT). 
Methods and Materials: All 15 patients entered on a prospective 
study had biopsy proven locally recurrent prostate carcinoma 
visible on MRI, at least 18 months after definitive RT, with > 6 
months PSA doubling time. The GTV was defined using 
multiparametric MRI (T2-weighted, diffusion-weighted, dynamic 
contrast-enhanced). The prostate gland and GTV contours were 
deformably co-registered to T2w images at time of 
brachytherapy after catheter placement using deformable image 
registration. CTV margin expansion (5 mm in all directions) was 
restricted to adjacent OARs and 2 mm beyond the prostate 
boundary where applicable. PTV margins of 2 mm cranio-caudally 
and 1mm elsewhere were then applied. A total dose of 26 Gy in 
two separate implants 7-14 days apart was delivered. No patient 
received androgen deprivation therapy. 
Results: Median follow up was 12 months (range, 3-24). The 
median age at time of enrollment was 72 years (range, 62-77). 
The median pre-brachytherapy PSA was 3.96 ng/ml (range, 1.68 
– 8.39). All patients had a single GTV. Median GTV and PTV 
volumes were 1.45 cc (range, 0.66-6.76) and 6.45 cc (range 3.5-
17.39), respectively. A median of eight catheters (range, 4-12) 
were used. Initial biochemical response after salvage 
brachytherapy was seen in all patients with 14 having > 50% 
reduction from baseline. To date 10 have achieved PSA < 1 
ng/ml, while 10 of 12 patients with > 12 months follow up have 
PSA level < 1 ng/ml. Of two patients who have experienced 
biochemical failure, one had imaging and biopsy evidence of a 
marginal recurrence. Acute toxicity (CTCAE v4.0) was mild. Only 
one patient had Grade 2 toxicity (temporary urinary 
catheterization after his second implant). All acute toxicity has 
resolved in patients who have greater than three months of 
follow up. 
Conclusions: MR-guided focal salvage HDR brachytherapy in 
patients treated with previous RT is associated with minimal 
acute toxicity and initial biochemical response appears 
promising. Further follow up will determine if this approach 
results in acceptable local/biochemical control and late toxicity. 
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Purpose: Exposure of the heart to radiation during radiotherapy 
for breast cancer has been shown to increase the rate of ischemic 
heart disease, with the increase being proportional to the mean 
dose to the heart. Although a significant reduction of heart dose 
has been shown with respiratory-gated irradiation of the left 
breast, there is currently no data on heart dose variation through 
the cardiac cycle. The purpose of this study was to assess dose 
variation to left coronary artery, left ventricle and heart during 
the cardiac cycle using dual source computed tomography 
(DSCT). 4D cardiac motion was used to investigate the potential 
dosimetric advantage of cardiac-gated radiotherapy.  
Methods and Materials: This is a prospective pilot study of 
patients with left-sided breast cancer treated with tangential 
breast irradiation. A planning scan and a contrast-injected 
